Since activation of the CAIP is largely through the activation of α7nAChR [18, 19], targeting α7nAChR for therapeutic purpose may achieve the goal of not only regressing endometriotic lesions but also improving the overall wellbeing of the patients with endometriosis. This evidence concerns the gene CHRNA7 and endometriosis.